- Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”
-
Fujii H, Iwaki M, Kamada Y
- KMID: 2554438
- Clin Mol Hepatol.
- 2024 Apr;30(2):281-283.
- doi: 10.3350/cmh.2024.0214
-
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis
-
Komori A
- KMID: 2554418
- Clin Mol Hepatol.
- 2024 Apr;30(2):157-159.
- doi: 10.3350/cmh.2024.0131
-
- CITED
-
- Close
- SHARE
-
- Close
- The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective
-
Pirola CJ, Sookoian S
- KMID: 2554424
- Clin Mol Hepatol.
- 2024 Apr;30(2):174-176.
- doi: 10.3350/cmh.2024.0082
-
- CITED
-
- Close
- SHARE
-
- Close
- Linvencovir: Paving the way for functional cure in hepatitis B
-
Yang J, Choi J
- KMID: 2554420
- Clin Mol Hepatol.
- 2024 Apr;30(2):164-165.
- doi: 10.3350/cmh.2024.0149
-
- CITED
-
- Close
- SHARE
-
- Close
- Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research
-
Tsai YN, Wu JL, Hsu YC
- KMID: 2554436
- Clin Mol Hepatol.
- 2024 Apr;30(2):276-278.
- doi: 10.3350/cmh.2024.0220
-
- CITED
-
- Close
- SHARE
-
- Close
- In response to: Steatotic liver disease-know your enemies
-
Le MH, Henry L, Nguyen MH
- KMID: 2554439
- Clin Mol Hepatol.
- 2024 Apr;30(2):284-286.
- doi: 10.3350/cmh.2024.0108
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”
-
Liaw YF
- KMID: 2554433
- Clin Mol Hepatol.
- 2024 Apr;30(2):269-271.
- doi: 10.3350/cmh.2024.0064
-
- CITED
-
- Close
- SHARE
-
- Close
- Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring
-
Tsai YN, Wu JL, Hsu YC
- KMID: 2554442
- Clin Mol Hepatol.
- 2024 Apr;30(2):293-296.
- doi: 10.3350/cmh.2024.0101
-
- CITED
-
- Close
- SHARE
-
- Close
- Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances
-
Xie L, Zhang L, Chen H, Yang YY, Wu J
- KMID: 2554437
- Clin Mol Hepatol.
- 2024 Apr;30(2):279-280.
- doi: 10.3350/cmh.2024.0191
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”
-
Jang BK
- KMID: 2554443
- Clin Mol Hepatol.
- 2024 Apr;30(2):297-298.
- doi: 10.3350/cmh.2024.0210
-
- CITED
-
- Close
- SHARE
-
- Close
- Toward hepatitis C virus elimination using artificial intelligence
-
Hur MH, Lee JH
- KMID: 2554415
- Clin Mol Hepatol.
- 2024 Apr;30(2):147-149.
- doi: 10.3350/cmh.2024.0135
-
- CITED
-
- Close
- SHARE
-
- Close
- JCAD, a new potential therapeutic target in cholestatic liver disease
-
Jang BK
- KMID: 2554421
- Clin Mol Hepatol.
- 2024 Apr;30(2):166-167.
- doi: 10.3350/cmh.2024.0128
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
-
Hong H, Choi J
- KMID: 2554434
- Clin Mol Hepatol.
- 2024 Apr;30(2):272-273.
- doi: 10.3350/cmh.2024.0123
-
- CITED
-
- Close
- SHARE
-
- Close
- Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
-
Suzuki H, Shimose S, Iwamoto H, Niizeki T, Kawaguchi T
- KMID: 2554431
- Clin Mol Hepatol.
- 2024 Apr;30(2):263-265.
- doi: 10.3350/cmh.2023.0557
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”
-
Jung S, Yoon S, Park JH, Lee YS, Yoo KH
- KMID: 2554440
- Clin Mol Hepatol.
- 2024 Apr;30(2):287-290.
- doi: 10.3350/cmh.2024.0136
-
- CITED
-
- Close
- SHARE
-
- Close
- Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma
-
Han JE, Cho HJ
- KMID: 2554419
- Clin Mol Hepatol.
- 2024 Apr;30(2):160-163.
- doi: 10.3350/cmh.2024.0141
-
- CITED
-
- Close
- SHARE
-
- Close
- Immunopathogenesis of liver fibrosis in steatotic liver disease
-
Woo C, Jeong WI
- KMID: 2554444
- Clin Mol Hepatol.
- 2024 Apr;30(2):299-302.
- doi: 10.3350/cmh.2024.0113
-
- CITED
-
- Close
- SHARE
-
- Close
- Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization
-
Rezaee-Zavareh MS, Kim N, Yang JD
- KMID: 2554416
- Clin Mol Hepatol.
- 2024 Apr;30(2):150-153.
- doi: 10.3350/cmh.2024.0116
-
- CITED
-
- Close
- SHARE
-
- Close
- Steatotic liver disease: Know your enemies
-
Mak LY
- KMID: 2554423
- Clin Mol Hepatol.
- 2024 Apr;30(2):171-173.
- doi: 10.3350/cmh.2024.0078
-
- CITED
-
- Close
- SHARE
-
- Close
- Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen
-
Huang CT, Tseng TC
- KMID: 2554417
- Clin Mol Hepatol.
- 2024 Apr;30(2):154-156.
- doi: 10.3350/cmh.2024.0120
-
- CITED
-
- Close
- SHARE
-
- Close
